Clinical Biotechnology

product pipeline / R&D affecting expense

“The effective income tax rate of 23.0% for the six months ended June 30, 2024 differed from the U.S. federal statutory rate of 21% primarily due to one-time impacts from acquisitions and income earned by certain of our foreign entities being taxed at higher rates than the U.S. federal statutory rate, the U.S. taxation of international operations with the expanded global footprint and transaction costs from the Howden Acquisition offset by research and development credits and excess tax benefits associated with share-based compensation.”

GTLS 10-Q

restructuring

“Changes to the assumptions and estimates used throughout the steps described above may result in a significantly different estimate of the fair value of the reporting units, which could result in a different assessment of the recoverability of goodwill and result in future impairment charges.”

GTLS 10-K

restructuring affecting expense

“These impacts were partially offset by a decrease in shutdown and severance related costs compared with the prior year.”

EBS 10-Q